Document is current
Any future updates will be listed below
-
Authors
Zhao, Yu
Zhu, Xiang-Yang
Ma, Wenqi https://orcid.org/0000-0002-0287-8496
Zhang, Ying
Yuan, Fei
Kim, Seo Rin
Tang, Hui
Jordan, Kyra
Lerman, Amir https://orcid.org/0000-0002-9446-5313
Tchkonia, Tamara
Kirkland, James L. https://orcid.org/0000-0003-1676-4905
Lerman, Lilach O. https://orcid.org/0000-0002-3271-3887
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK120292, DK122734)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG013925, AG062104)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL158691)
- License Information
-
More Information
Article History
Received: 29 February 2024
Revised: 7 April 2025
Accepted: 14 April 2025
First Online: 10 May 2025
Competing interests
: This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and conducted in compliance with Mayo Clinic conflict of interest policies. The other authors declare no conflicts of interest. Dr. Lerman is an advisor to CureSpec, RiboCure, and Cellergy. Drs. Tchkonia and Kirkland have patents and pending patents covering senolytic drugs and their uses that are held by Mayo Clinic.
: All animal studies comply with the Animal Welfare Act (AWA) were approved by the Mayo Clinic Institutional Animal Care and Use Committee (approval no. A00002628-17). All human procedures in compliance with the principles of the Declaration of Helsinki were approved by Zhongda Hospital Affiliated to Southeast University Clinical Research Ethics Committee, and informed consent was obtained from all subjects (approval no. 2023ZDSYLL087-P01).
